SAN DIEGO, CA, UNITED STATES, August 4, 2026 /EINPresswire.com/ -- Key Takeaways Investigational New Drug (IND) ...

The power of CRISPR became definitively clear when the first CRISPR-based gene therapy, Casgevy (exa-cel), won regulatory approvals for the treatment of sickle cell disease. But CRISPR’s applications ...

For decades, the pharmaceutical industry has discussed moving away from in vivo models in preclinical research. Now, it’s more than a conversation. The FDA’s roadmap for reducing animal testing, ...

Capivasertib and venetoclax combination shows efficacy in PTEN-wildtype and PTEN-deficient diffuse large B-cell lymphoma (DLBCL) models, inducing caspase and PARP cleavage and inhibiting tumor growth.

Early detection of safety liabilities of new therapies is a critical biopharmaceutical challenge. Addressing this challenge could significantly advance drug discovery. Advanced human cell models, ...

In the UK, there was a case where TGN1412, an immunotherapy under development, triggered a cytokine storm within hours of administration to humans, leading to multiple organ failure. Another example, ...

Genetically-humanized FcRn mice provide translational pharmacokinetics (PK) and pharmacodynamics (PD) data for antibody-based therapeutics. The image illustrates a therapeutic antibody (blue) adhering ...

This article and associated images are based on a poster originally authored by Kieran Casey, Yuzhou Xu, Jichuan Zhang, Shuyue Wang, Yanfei Hu, Ye Tian, Min Lyu, Ziyu Chen, Ya Xu, Qikuan Chen and ...

New findings showcase the potential of in vivo CAR-M technology as an effective, off-the-shelf treatment for hepatocellular carcinoma (HCC) Pre-clinical results showed that the novel in vivo anti-GPC3 ...

Cancer is a leading cause of death worldwide, and among all cancers, colorectal cancer ranks second in mortality, responsible for more than 900,000 deaths in 2020. In the U.S., rates of colorectal ...